Cupps Capital Management’s Biogen BIIB Stock Holding History

Cupps Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,575	Closed	-$665K	–	193
2015 Q1	$665K	Buy	+1,575	New	+$621K	0.06%	144
2014 Q4	–	Sell	-1,755	Closed	-$580K	–	223
2014 Q3	$580K	Buy	1,755 +420	+31%	+$138K	0.05%	152
2014 Q2	$420K	Buy	1,335 +635	+91%	+$191K	0.03%	159
2014 Q1	$214K	Buy	+700	New	+$222K	0.02%	152

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Cupps Capital Management's BIIB Position: Q2 2015 in Review

Cupps Capital Management sold out of Biogen (BIIB) in Q2 2015, closing a stake of 1,575 shares — an estimated $665K sold.

Cupps Capital Management first reported a position in BIIB in Q1 2014 and held it in 4 quarters. The position peaked at $665K in Q1 2015. 974 funds tracked by Wall St. Rank hold BIIB as of Q2 2015.

Cupps Capital Management reported no remaining Biogen position as of Q2 2015 after selling out during the quarter.
Cupps Capital Management sold 1,575 Biogen shares in Q2 2015, an estimated $665K.
Cupps Capital Management first reported a position in Biogen in Q1 2014 and held it in 4 quarters.
Cupps Capital Management's Biogen position peaked at $665K in Q1 2015.
974 funds tracked by Wall St. Rank held Biogen as of Q2 2015.

Based on Cupps Capital Management's 13F filing for Q2 2015, filed 6 Aug 2015.